SCHEMBL1241268

SCHEMBL1241268

CN1CCCC1CCNS(=O)(=O)c1ccc2c(c1)CN(CC1CCCCC1)CC2

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.46
HTR7 P34969 5/20 0.43
TSHR P16473 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MOGAT2 Q3SYC2 4/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400927 1.00 HRH3 (0.46) HRH3HTR7TSHRALDH1A1MOGAT2
Water SCHEMBL16161850 0.99 HRH3 (0.46) HRH3HTR7TSHRALDH1A1MOGAT2
Oxalic Acid SCHEMBL1241171 0.96 HRH3 (0.44) HRH3HTR7TSHRALDH1A1MOGAT2
SCHEMBL5630601 0.96 HTR7 (0.45) HRH3HTR7TSHRALDH1A1TP53
Fumaric Acid SCHEMBL9898674 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2
Fumaric Acid SCHEMBL9898673 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2
Fumaric Acid SCHEMBL27987046 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2
Fumaric Acid SCHEMBL9898162 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2
Fumaric Acid SCHEMBL2435679 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2
Fumaric Acid SCHEMBL2435682 0.93 TSHR (0.41) HRH3HTR7TSHRALDH1A1MOGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1956962-B Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS 2014-08-20 CN claimed
EP-1753725-B1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI SA (FR) 2013-02-27 EP claimed
US-8273733-B2 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics SANOFI (FR) 2012-09-25 US claimed
US-20110028475-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2011-02-03 US claimed
US-7833999-B2 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics SANOFI-AVENTIS (FR) 2010-11-16 US claimed
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US claimed
CN-1956962-A Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS (FR) 2007-05-02 CN claimed
EP-1753725-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2007-02-21 EP claimed
WO-2005118547-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2005-12-15 WO claimed
EP-2833887-A1 AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE SANOFI (FR) 2015-02-11 EP disclosed
CN-1956962-B Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS 2014-08-20 CN disclosed
WO-2013150150-A1 AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE SANOFI (FR) 2013-10-10 WO disclosed
US-8524700-B2 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics SANOFI (FR) 2013-09-03 US disclosed
US-8524700-B2 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics SANOFI (FR) 2013-09-03 US disclosed
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US disclosed
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US disclosed
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2007-05-10 US disclosed
CN-1956962-A Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy SANOFI AVENTIS (FR) 2007-05-02 CN disclosed
EP-1753725-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2007-02-21 EP disclosed
WO-2005118547-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105834-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS BACE1, SLC6A2, KCNQ2 HRH3 128/4885HTR7 175/4885TSHR 2053/4885
US-20110028475-A1 TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS BACE1, HTR2B, KCNQ2 HRH3 104/4885HTR7 227/4885TSHR 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.